<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Juvenile systemic sclerosis (scleroderma): Assessment and approaches to treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Juvenile systemic sclerosis (scleroderma): Assessment and approaches to treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Juvenile systemic sclerosis (scleroderma): Assessment and approaches to treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francesco Zulian, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suzanne C Li, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H37551736">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Scleroderma is a group of diseases that vary in severity and that can occur at any stage of life, although the clinical patterns of scleroderma in children differ from those in adulthood [
         <a href="#rid1">
          1
         </a>
         ]. The predominant form of scleroderma in childhood is localized scleroderma. The juvenile systemic sclerosis (JSSc) form of scleroderma is uncommon but generally has more serious, potentially life-threatening morbidity than other sclerotic disorders.
        </p>
        <p>
         Treatment is based upon disease severity, activity, and progression. However, laboratory assessment of these is difficult. Thus, regular follow-up and clinical review are the cornerstones of monitoring.
        </p>
        <p>
         This topic reviews monitoring and management of JSSc. The classification, clinical presentation, and diagnosis JSSc are discussed in detail separately. Localized scleroderma in children and the pathogenesis of SSc are also discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">
          "Juvenile localized scleroderma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p>
         SSc in adults is also discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3098508264">
         <span class="h1">
          ORGAN SYSTEM MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many serologic markers of activity, such as intercellular adhesion molecule 1 (ICAM-1), collagen propeptides, products of type I collagen breakdown, immunologic markers (soluble interleukin 2 [sIL-2] receptor, neopterin), and vascular activation markers (E-selectin, thrombomodulin, von Willebrand factor), have been proposed throughout the years, but none have shown significant correlation with the clinical status of the patient. Thus, patients are monitored clinically rather than through laboratory markers of disease activity.
        </p>
        <p>
         Organ systems are monitored for involvement, usually every three to four months as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular
         </strong>
         – Although uncommon, cardiac involvement is the leading cause of death in JSSc. Cardiac monitoring includes a standard electrocardiogram (ECG), echocardiogram, and 24-hour cardiac monitoring for arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ECG abnormalities include first-degree heart block, right and left bundle branch block, premature atrial and ventricular contractions, and nonspecific T-wave changes. The most frequent cardiac arrhythmias in children with JSSc are supraventricular, whereas ventricular arrhythmias are uncommon [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Echocardiographic abnormalities include pericardial effusions, thickening of the left ventricular wall, and decreased left ventricular compliance. The two-dimensional echocardiogram is important in confirming early pulmonary hypertension by documentation of a dilated right ventricle with thickening of the ventricular wall and straightening of the septum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Right heart catheterization provides definitive confirmation but is indicated only in selected cases; for example, when echocardiographic data suggest a pulmonary artery hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional noninvasive and sensitive assessment tools for the early detection of cardiac involvement include cardiac magnetic resonance imaging (MRI) and speckle tracking strain rate (S-SR) echocardiography (STE) [
         <a href="#rid3">
          3
         </a>
         ]. STE, if available, is indicated at every follow-up visit, especially in patients with a severe course of disease. Cardiac MRI is indicated when standard echocardiography or STE suggest myocardial abnormalities. As an example, myocardial fibrosis was detected using late-enhancement images (LGEs) on MRI in 15 to 66 percent of asymptomatic adult patients [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory
         </strong>
         – Pulmonary function testing (PFT) is routinely used to detect early signs of respiratory involvement. Characteristic findings of the respiratory tract involvement include a decrease in timed vital capacity (FVC), forced expiratory flow (FEV), and diffusing capacity of the lungs for carbon monoxide (DLCO) consistent with a restrictive pattern [
         <a href="#rid7">
          7
         </a>
         ]. FVC is less sensitive but more specific than DLCO in detecting potential abnormalities on high-resolution computed tomography (HRCT). Therefore, PFTs should be used in tandem with HRCT for the screening of interstitial lung disease (ILD) in JSSc [
         <a href="#rid8">
          8
         </a>
         ]. The most frequent findings on HRCT are ground-glass opacification, subpleural micronodules, linear opacities, and, later in the disease process, honeycombing [
         <a href="#rid9">
          9,10
         </a>
         ]. A six-minute walk test is another potential tool for monitoring pulmonary function [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – Vasculopathy and inflammation leading to fibrosis can manifest in the entire gastrointestinal tract, from mouth to anus. Gastrointestinal involvement is often asymptomatic initially. Thus, imaging is necessary for diagnosis. The most common gastrointestinal problem encountered in JSSc is esophageal dysmotility, which causes poor weight gain and very low body mass index (BMI), gastroesophageal reflux disease (GERD) with acid sequela, and silent aspiration of gastrointestinal contents. Esophageal scintigraphy or cine-esophagram (barium swallow) can document decreased peristalsis in the lower part of the esophagus with distal dilation, strictures, and shortening. Esophageal manometry and 24-hour pH probe monitoring represent more sensitive indicators of diminished lower sphincter tone and presence of reflux, respectively [
         <a href="#rid12">
          12
         </a>
         ]. These two studies are both performed if scintigraphy or esophagram is abnormal and the patient is able to tolerate and cooperate with the procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin –
         </strong>
         Skin induration is measured using the Modified Rodnan Skin Score (mRSS)  (
         <a class="graphic graphic_figure graphicRef97759" href="/z/d/graphic/97759.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef96747" href="/z/d/graphic/96747.html" rel="external">
          figure 2
         </a>
         ), corrected for BMI and the Tanner stage [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7544.html" rel="external">
          "Pretreatment evaluation of adults with systemic sclerosis (scleroderma)", section on 'Skin involvement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microvascular
         </strong>
         – Capillary abnormalities can be detected by nailfold videocapillaroscopy (NVC) and categorized into early, active, and late stages  (
         <a class="graphic graphic_figure graphicRef94667" href="/z/d/graphic/94667.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef79285" href="/z/d/graphic/79285.html" rel="external">
          picture 1
         </a>
         ). An international consensus study reported the specific patterns NVC in children and adolescents with connective tissues diseases. This represents a useful tool for the diagnosis and assessment of JSSc [
         <a href="#rid14">
          14
         </a>
         ]. The early SSc pattern is characterized by a few enlarged/ectatic capillaries and hemorrhages but normal density of capillaries. In the active stage, multiple giant and enlarged/ectatic capillaries with hemorrhages and disordered capillaries due to capillary loss are seen. The late pattern is distinguished by completely disturbed architecture with loss of multiple capillaries and bushy capillaries (neovascularization), with giant capillaries and hemorrhages only occasionally visible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults, the response to treatment for Raynaud phenomenon (RP) is assessed by patient/clinician RP activity assessment, RP frequency (number of attacks per week), and RP duration (mean duration of RP attacks per week) [
         <a href="#rid15">
          15
         </a>
         ]. The same approach is taken in children, although it has not been validated in any studies. Digital ulcers as a complication of RP or vasculitis can be evaluated by both digital ulcer count and degree of pain by visual analog scale (VAS). An innovative technique for RP assessment is based on the use of infrared thermography after cold challenge. This gives an indirect measure of the microvascular flow (damage) and is useful in differentiating RP secondary to SSc from primary RP and acrocyanosis if the diagnosis is in question [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Musculoskeletal
         </strong>
         – Osteoarticular involvement is assessed by evaluating for the presence of arthritis, limited range of motion in the joints, and tendon friction rubs. Imaging can be used to assess for tenosynovitis, arthritis, fasciitis, myositis, and bony changes associated with arthropathy. The childhood Myositis Activity Score (c-MAS) is used to assess muscle strength  (
         <a class="graphic graphic_table graphicRef104902" href="/z/d/graphic/104902.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney –
         </strong>
         Kidney function is monitored by standard urine analyses and creatinine clearance with calculation of the glomerular filtration rate. Patients on glucocorticoids should have their blood pressure and kidney function carefully monitored (eg, every one to two months if the patient is on &gt;0.5 mg/kg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) because of a potential increased risk of scleroderma renal crisis, particularly in patients with diffuse SSc and high or rapidly progressing skin score.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4027182595">
         <span class="h1">
          SCORING TOOLS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is significant variability in disease severity in children. Thus, a multidimensional severity score, named "J4S," an acronym that stands for Juvenile Systemic Sclerosis Severity Score, including growth parameters, skin, and internal organ involvement, was designed to follow JSSc patients over time  (
         <a class="graphic graphic_table graphicRef95200" href="/z/d/graphic/95200.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. The J4S includes a general category and eight organ system categories: vascular, cutaneous, osteoarticular, muscular, gastrointestinal, respiratory, cardiac, and renal. Each category is scored from 0 to 4 and then weighted based upon the clinical importance of the organ system involved. The parameters that are more sensitive to change are Raynaud phenomenon (RP), number of digital scars, and number of ulcers/gangrene for vascular involvement and the body mass index (BMI) for general assessment. J4S may have several applications for the pediatric age group since it can be used to guide decision making in daily clinical practice, compare study populations, and identify potentially reversible aspects of the disease.
        </p>
        <p>
         Two tools that measure patient function and quality of life have been validated for children with juvenile idiopathic arthritis and juvenile dermatomyositis: the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ-PF50). Although these two instruments also appear to be excellent tools to measure clinical outcomes in children with SSc, especially in clinical trials, validation of these measures is required.
        </p>
        <p class="headingAnchor" id="H1152027304">
         <span class="h1">
          MANAGEMENT OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         A carefully designed treatment program is based upon disease severity and progression. This multi-team approach includes [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin care
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular protection by avoidance of cold and sudden temperature changes
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exercise program to maintain functional ability
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychologic and social support
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disease-modifying and organ-targeted pharmacologic therapy including discussions with the patient and caregiver(s) of available options
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgical procedures, if needed
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Education of the patient and caregiver(s) to help understand the complexity of management decisions, guide decision making, and facilitate adherence with an often difficult and time-consuming treatment plan
        </p>
        <p>
        </p>
        <p>
         The pharmacologic management of patients with JSSc is challenging because the etiology and pathogenesis are poorly understood and the disease is heterogenous with variable progression [
         <a href="#rid20">
          20
         </a>
         ]. The treatment of JSSc focuses on controlling symptoms and minimizing progression of internal organ involvement. No drug has been shown to be of unequivocal benefit in either children or adults with SSc, and there are no randomized trials of these therapies in children with JSSc. In addition, many of these drugs have significant side effects. As a result, careful consideration should be made on which treatment is more appropriate for each specific clinical picture, always balancing the known toxicities of the medications against the unknown possible therapeutic gain.
        </p>
        <p>
         Options for therapeutic approaches include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunomodulatory therapy, which is directed at controlling the underlying disease process
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organ-targeted therapy, which is directed toward complications of specifically involved organs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Experimental therapy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2827236445">
         <span class="h1">
          GENERAL MEASURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonpharmacologic measures include the following [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General skin care includes avoiding irritating or drying substances and the daily application of
         <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">
          lanolin
         </a>
         or water-soluble cream as an emollient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients and caregivers should be told to avoid cold, trauma, heat, and sun exposure. Cold and trauma can exacerbate symptoms. Especially in cold climates, the caregiver should keep the child warm by maintaining a satisfactory household temperature and by use of appropriate clothing, including well-insulated mittens (not gloves), boots, and a hat. These children are also susceptible to hyperpigmentation from sunlight and have difficulty in dissipating heat through sclerotic skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The child should be encouraged to be as physically active as possible. Physiotherapy will help maintain functional ability, muscle strength, and joint movement while preventing flexion contractures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of corrective splints may be necessary to treat or prevent contractures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with gastrointestinal involvement, small, frequent meals; avoiding eating before bedtime; and raising the head of the bed are advised.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3667259936">
         <span class="h1">
          IMMUNOMODULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An activated immune system may be an important stimulus to both fibrotic and vascular lesions in SSc. The maximum damaging effect is most likely in the early stages of the disease. Initial immune activation may create autocrine loops through the production of cytokines and growth factors, for example, which require no further stimulus to perpetuate fibrotic and vascular lesions.
        </p>
        <p>
         Many immunotherapies are used in adults with SSc with varying degrees of efficacy. These therapies are selected case by case and usually are reserved for patients with severe, refractory diffuse cutaneous SSc (dcSSc) or overlap syndromes. The following have the most reliable efficacy and may be used in children:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
          mofetil –
         </strong>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil (MMF) inhibits fibrosis by the direct action on fibroblasts, the inhibition of their proliferation, and the reduction of tissue accumulation of activated myofibroblasts [
         <a href="#rid21">
          21
         </a>
         ].
         <strong>
         </strong>
         Several observational studies have reported promising results with MMF for skin and pulmonary fibrosis [
         <a href="#rid22">
          22-24
         </a>
         ]. One large observational study, including 326 patients from European centers, found that MMF was well tolerated and associated with improvement in skin disease over 12 months [
         <a href="#rid25">
          25
         </a>
         ]. Another study comparing oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         with MMF showed benefit for lung fibrosis and skin in both treatment arms [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids –
         </strong>
         High-dose systemic glucocorticoids are potentially toxic and, in adults, have been implicated in precipitating renal crisis [
         <a href="#rid27">
          27
         </a>
         ]. Glucocorticoids should be restricted to patients with myositis, active fibrosing alveolitis, symptomatic serositis, the early edematous phase of the skin disease, active arthritis, and/or tenosynovitis. The lowest possible effective dose should be used in these settings, preferably below 0.3 mg/kg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclophosphamide
         </strong>
         <strong>
          –
         </strong>
         The role of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in SSc remains uncertain. Its efficacy as a single agent is variable but, in combination with glucocorticoids or plasma exchange, is possibly efficacious in patients with fibrosing alveolitis who do not yet have advanced fibrosis [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3918417597">
         <span class="h1">
          ORGAN-TARGETED THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) Scleroderma Trials and Research (EUSTAR) group has established evidence-based recommendations for treatment of specific organ involvement in SSc [
         <a href="#rid29">
          29
         </a>
         ]. These recommendations are based upon observational studies and randomized trials in adults. However, there are no validated recommendations for JSSc. As such, a European project called Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE) was carried out to optimize and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases [
         <a href="#rid30">
          30
         </a>
         ]. As part of this effort, an international committee of experts in JSSc was created for the development of specific consensus-based recommendations [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Surgical procedures are variable and may include orthopedic procedures for tendon release, gastrointestinal surgical treatments for severe gastroesophageal reflux disease (GERD), and calcium removal in case of tumoral calcinosis.
        </p>
        <p>
         In the following section, we present organ-targeted treatment strategies for JSSc based upon the SHARE recommendations [
         <a href="#rid31">
          31
         </a>
         ], international congresses and meetings, and adult patient guidelines [
         <a href="#rid29">
          29
         </a>
         ]. Pediatric-specific literature is reviewed here. A more complete discussion on organ-based treatment for SSc is found elsewhere in multiple organ-specific topics and an overview. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2366324000">
         <span class="h2">
          Vascular involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasodilator agents are often used in patients with vascular involvement, mainly manifesting as Raynaud phenomenon (RP) and digital ulcerations or lung vascular disease (pulmonary hypertension). Specific treatment of RP is used in patients who do not respond to avoidance of precipitating circumstances such as cold or emotional stress. (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management", section on 'General measures'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Raynaud phenomenon'
         </a>
         .)
        </p>
        <p>
         The use of vasodilator agents in patients with JSSc is rather common, especially for vasospastic phenomenon of the extremities, despite the limited published evidence. The most widely used vasodilators are the calcium channel blockers (CCBs), which have been demonstrated to reduce the frequency and severity of ischemic attacks in patients with SSc [
         <a href="#rid32">
          32
         </a>
         ]. Of these,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         is the most commonly used, and a sustained-release formulation is typically recommended for ease of administration. Phosphodiesterase inhibitors, specifically phosphodiesterase-5 (PDE-5) inhibitors, are an alternative for moderate-to-severe RP, typically associated with digital ulcers, or in patients unable to tolerate or who are refractory to CCB treatment. A meta-analysis of randomized, controlled trials on PDE-5 inhibitors for RP including
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         , and
         <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">
          vardenafil
         </a>
         demonstrated significant benefit for all agents, with reduction in frequency of RP attacks [
         <a href="#rid33">
          33
         </a>
         ]. Intravenous prostanoids such as the prostaglandin,
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         , are used if other therapy fails [
         <a href="#rid29">
          29
         </a>
         ]. Data from a study on a small group of pediatric patients treated with iloprost infusions for ischemic digits and digital ulcerations suggest that these agents are effective and have a good safety profile [
         <a href="#rid15">
          15
         </a>
         ]. Use of these drugs for RP is off label. Treatment of RP is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia"
         </a>
         .)
        </p>
        <p>
         Digital ulcers are another severe and disabling complication of JSSc. In view of overall risk-to-benefit considerations, CCBs and PDE-5 inhibitors are typically used as first-line therapy in SSc-related digital ulcers [
         <a href="#rid32">
          32
         </a>
         ]. Prostanoids are used as first-choice treatment in rapidly progressive digital ulcers or in case of CCB resistance, with the same modalities as in severe RP [
         <a href="#rid15">
          15
         </a>
         ]. Endothelin 1, a potent vasoconstrictor and smooth muscle mitogen, is a possible target in patients with digital ulcers.
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          Bosentan
         </a>
         , a dual endothelin receptor antagonist, is recommended in the adult SSc population both for preventing digital ulcerations and for pulmonary hypertension [
         <a href="#rid29">
          29
         </a>
         ]. Little evidence is available in children regarding use of bosentan for digital ulcerations [
         <a href="#rid34">
          34
         </a>
         ]. However, the SHARE experts committee agree that bosentan is an option in patients with JSSc who have digital ulcerations refractory to other therapies and/or pulmonary hypertension [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Raynaud phenomenon'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2649468673">
         <span class="h2">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary alveolitis is predominant early in the course of interstitial lung disease (ILD) and later progresses to fibrosis. ILD is present in approximately one-third of JSSc patients and represents the main cause of SSc-related morbidity and death both in adults and children [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         Despite this high frequency, there are no published treatment studies of ILD in children with JSSc. SHARE guidelines
         <sup>
         </sup>
         suggest
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for patients with SSc-related ILD [
         <a href="#rid31">
          31
         </a>
         ] based upon two randomized trials in adults [
         <a href="#rid26">
          26,37
         </a>
         ]. Despite its known toxicity, cyclophosphamide (at a dose of 500 to 750 mg/m
         <sup>
          2
         </sup>
         once a month, maximum 1 g, intravenous pulse) is used in European pediatric scleroderma centers for JSSc pulmonary and cardiac involvement. However, most clinicians tend to use
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF; 500 to 750 mg/m
         <sup>
          2
         </sup>
         /day) rather than cyclophosphamide (dosing of 1500 mg twice a day) as first-line treatment based upon comparable efficacy and better adverse effect profile (less cytopenias and infections) [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         In an adult study, the use of both regimens resulted in significant improvements in prespecified measures of lung function, dyspnea, lung imaging, and skin disease [
         <a href="#rid26">
          26
         </a>
         ]. As expected, MMF was better tolerated and associated with less toxicity than
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . The recommended length of MMF treatment is still empiric, and most experts treat at least three to four years after stabilization of lung function. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6374.html" rel="external">
          "Approach to the infant and child with diffuse lung disease (interstitial lung disease)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Organ involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3290756249">
         <span class="h2">
          Cardiac complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac complications of JSSc are either primary (myocardial damage, fibrosis of the conduction system, and pericardial effusion) or secondary to pulmonary arterial hypertension [
         <a href="#rid39">
          39
         </a>
         ]. Although rare, cardiac involvement is a significant cause of morbidity among children with JSSc, and cardiorespiratory complications, together with ILD, are the leading cause of death. Thus, the treatment of the cardiac complications is the same as for ILD. (See
         <a class="local">
          'Interstitial lung disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Organ involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2334172995">
         <span class="h2">
          Skin involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the lack of published trials in children, the SHARE guidelines recommend the use of low-dose systemic glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.3 to 0.5 mg/kg/day for two to three months) in the active inflammatory phase of the disease, usually in combination with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (at a dose of 15 mg/m
         <sup>
          2
         </sup>
         as a single oral or subcutaneous dose per week) or an alternative disease-modifying antirheumatic drug (DMARD) [
         <a href="#rid31">
          31
         </a>
         ]. The combination of systemic glucocorticoids and methotrexate is widely used in JSSc and appears to have a good safety profile. After the first three months of treatment, prednisone can be tapered down until stopping while methotrexate or the alternative DMARD is continued. In adults with SSc, results in randomized trials were inconclusive for methotrexate [
         <a href="#rid40">
          40,41
         </a>
         ]. Nevertheless, the EULAR recommendations for treatment of SSc still support the use of methotrexate for skin disease [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Skin changes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Skin involvement'
         </a>
         .)
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) is an option in patients who do not tolerate the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper and are not controlled on
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         alone (methotrexate-refractory disease). Studies in adults have reported positive effects, mainly on cutaneous and pulmonary involvement, with good drug tolerance [
         <a href="#rid22">
          22,37,42
         </a>
         ]. MMF has proven histologic and transcription efficacy, with significant decreases in inflammatory infiltrate and microarray inflammatory gene expression profiles when comparing pre- with post-treatment skin biopsy specimens [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Skin involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">
          "Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4228159162">
         <span class="h2">
          Kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis for renal crisis was uniformly dismal until the introduction of angiotensin-converting enzyme (ACE) inhibitors (eg,
         <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">
          captopril
         </a>
         or
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         ) brought about a remarkable improvement in the outlook for prevention of vascular damage, effective long-term control of blood pressure, and stabilization of kidney function. Conversely, published evidence does not support the preventive use of ACE inhibitors to decrease the risk of development of renal crisis [
         <a href="#rid29">
          29
         </a>
         ]. Management of kidney disease in SSc, including renal crisis, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Kidney involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">
          "Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Organ involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2819598814">
         <span class="h2">
          Musculoskeletal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of musculoskeletal involvement (myositis, arthritis, and tenosynovitis) includes the use systemic glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.3 to 0.5 mg/kg/day for two to three months followed by tapering down until stopping or to the minimal dose that is able to control inflammation) in combination with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . The use of potential nephrotoxins such as nonsteroidal antiinflammatory drugs (NSAIDs) should be avoided. Management of neuromuscular complications of SSc is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7550.html" rel="external">
          "Neuromuscular manifestations of systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Musculoskeletal features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Musculoskeletal involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1412051250">
         <span class="h2">
          Gastrointestinal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few studies in children with JSSc address the most effective management for gastrointestinal disease, which includes GERD, erosive esophagitis, esophageal dysmotility, diarrhea, constipation, and malabsorption due to small intestine bacterial overgrowth. GERD should be treated even in asymptomatic patients. GERD is managed in part by lifestyle and dietary changes, including nighttime routine to avoid chronic microaspiration while sleeping, which is associated with ILD in adults and children [
         <a href="#rid44">
          44
         </a>
         ]. Lifestyle changes include elevating the head of the bed, avoiding meals less than three hours before bed, and eating small, frequent meals low in fat and residue with plenty of water to facilitate passage of food. Proton pump inhibitors (PPIs) are still the drugs of choice, even in the early phase of disease, for prevention of SSc-related GERD and esophageal ulcers. JSSc patients on PPIs are at increased risk of hypochlorhydria, gastric bacterial colonization, and enteric infection, in particular,
         <em>
          Clostridium difficile
         </em>
         , as well as hypomagnesemia and vitamin B12 malabsorption and acute interstitial nephritis; therefore, their use should be closely monitored [
         <a href="#rid45">
          45,46
         </a>
         ]. The management of GERD in children is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5900.html" rel="external">
          "Management of gastroesophageal reflux disease in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">
          "Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis", section on 'Organ involvement'
         </a>
         .)
        </p>
        <p>
         Esophageal dysmotility is common and typically presents as dysphagia or a feeling of food getting stuck in the throat or chest area. Several studies in adults suggest that prokinetic drugs such as
         <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">
          domperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">
          cyproheptadine
         </a>
         are the preferred agents for initial therapy [
         <a href="#rid47">
          47
         </a>
         ]. Low-dose erythromycin or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         two to three times a day lowers esophageal pressure and increases gastric contractions to move food through the esophagus, whereas cyproheptadine assists in gut motility, gastric accommodation, and appetite stimulation [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Malabsorption is difficult to manage. Diarrhea and bloating are most often caused by bacterial overgrowth and are treated by rotating antibiotics because continuous therapy with one agent may result in the emergence of resistant organisms. Treatment is based upon adult SSc data. The choice of antibiotic is usually empirical and includes
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         or oral cephalosporins. In refractory cases,
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         can be added for five to seven days to treat anaerobic flora [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7556.html" rel="external">
          "Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p>
         Vitamins B12, vitamin D3, and iron for malabsorption and probiotics to improve bloating may be also indicated [
         <a href="#rid49">
          49
         </a>
         ]. Acute intestinal pseudoobstruction can be treated with bowel rest and hydration. Constipation due to colonic sclerosis can be managed by hydration and dietary fiber.
        </p>
        <p>
         A growing child or adolescent with SSc is vulnerable to malnutrition and growth delay. The causes can be multiple, from malabsorption or poor oral intake secondary to functional or psychological reasons. In a patient with decreasing or low body mass index (BMI) Z-score, referral to a multidisciplinary team (gastroenterologist, nutritionist, dentist, and/or mental health provider) is indicated [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3090866047">
         <span class="h1">
          EXPERIMENTAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several drugs are under evaluation to treat different aspects of SSc in adults, including
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         [
         <a href="#rid51">
          51,52
         </a>
         ]. Investigational agents for SSc are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">
          "Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Investigational approaches'
         </a>
         .)
        </p>
        <p>
         A few studies in adults suggest that
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         alone or in addition to
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) is beneficial for lung and cardiac involvement [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         Only one pediatric case series of four patients treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in addition to MMF for one year has been reported [
         <a href="#rid55">
          55
         </a>
         ]. In this series, all patients showed a significant decrease in the number and duration of Raynaud phenomenon (RP) attacks and degree of cutaneous involvement. Two patients showed a global cardiac improvement and decreased severity score (J4S). The other two patients had improved respiratory function and one also resolution of arrhythmia and myositis.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         , a tyrosine kinase inhibitor that halts fibroblast and myofibroblast proliferation and thus limits extracellular matrix accumulation, is a potential option for patients who have evidence of fibrotic lung disease on high-resolution computed tomography (HRCT). Nintedanib has been shown to slow the respiratory disease progression in adult SSc–associated interstitial lung disease (ILD) [
         <a href="#rid56">
          56
         </a>
         ]. Unfortunately, nausea, diarrhea, and weight loss are common and limit its use.
        </p>
        <p>
         One of the most aggressive approaches to therapy is immunoablation followed by reconstitution with autologous hemopoietic cell transplantation (HCT). The rationale for this therapy is the ablation of self-reactive lymphocytic clones that are potentially responsible for the disease process. Autologous HCT has shown respiratory benefit in patients with severe diffuse cutaneous SSc. The beneficial effect of HCT was demonstrated with decreased pulmonary, kidney, and cardiac morbidity in two trials, one in Europe and one in North America [
         <a href="#rid57">
          57,58
         </a>
         ]. Although the mortality rate in SSc-ILD seems to improve following HCT, there remains significant initial transplant-related mortality (6 percent). This, and the high incidence of other treatment-related adverse effects, has limited its use in pediatric patients.
        </p>
        <p>
         Based upon emerging trial data, autologous HCT may be most beneficial in selected patients with early, severe diffuse SSc. These patients may have moderate internal organ involvement and progressive disease despite an initial trial of immunosuppression. The lack of comorbidities, the more defined screening guidelines for JSSc patient selection, and the earlier referral of patients to specialized pediatric centers with expertise in both JSSc and transplantation are reasons for reconsidering HCT as a potential therapeutic strategy for children, particularly those who are early in the disease course (three years or less from the first non-Raynaud sign or symptom) before irreversible damage has occurred [
         <a href="#rid59">
          59
         </a>
         ]. HCT for SSc is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7549.html" rel="external">
          "Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)", section on 'Autologous stem cell transplantation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3340172015">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the prognosis of SSc in children appears better than in adults. Survival rates for childhood-onset SSc at 5, 10, 15, and 20 years after diagnosis are 89, 80 to 87, 74 to 87, and 69 to 82 percent, respectively [
         <a href="#rid35">
          35,60,61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Mortality'
         </a>
         .)
        </p>
        <p>
         Children with SSc have two possible courses. The vast majority manifest a slow disease course with lower mortality. In these patients, JSSc is usually most active during the first three to five years following onset of disease. Typical findings include fatigue, weight loss, rapidly advancing skin induration, arthritis, myositis, and tendonitis. Visceral involvement also commonly occurs during this period. After the first five years of disease, constitutional symptoms often abate, skin abnormalities may stabilize or occasionally improve, but visceral involvement may progress.
        </p>
        <p>
         However, approximately 10 percent of patients with JSSc have rapid development of internal organ involvement leading to severe disability and eventually to death [
         <a href="#rid35">
          35,62,63
         </a>
         ]. This category includes also the sine scleroderma subtype [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         The most common causes of death in children are related to the involvement of the cardiac, kidney, and pulmonary systems. Cardiomyopathy is a leading cause of early death, especially in children [
         <a href="#rid35">
          35,63
         </a>
         ]. This complication is rare and usually associated with diffuse cutaneous disease and features of polymyositis. Aggressive immunosuppressive treatment is effective on muscle, skin, and lung involvement but may not prevent progression of myocardial dysfunction [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1773271254">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/134214.html" rel="external">
          "Society guideline links: Mixed connective tissue disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118282.html" rel="external">
          "Society guideline links: Systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1439868971">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organ system monitoring and scoring tools
         </strong>
         – Treatment is based upon disease severity, activity, and progression. However, laboratory assessment of these is difficult. Thus, regular follow-up and clinical review are used. Sequential skin scores should be recorded, and objective assessment is necessary for organ-based complications, such as pulmonary fibrosis, pulmonary hypertension, or kidney involvement. A multidimensional severity score, the Juvenile Systemic Sclerosis Severity Score (J4S), provides a more global index of severity  (
         <a class="graphic graphic_table graphicRef95200" href="/z/d/graphic/95200.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Organ system monitoring'
         </a>
         above and
         <a class="local">
          'Scoring tools'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The modified Rodnan skin score (mRSS) is a widely accepted tool for evaluating the extent of skin fibrosis  (
         <a class="graphic graphic_figure graphicRef97759" href="/z/d/graphic/97759.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef96747" href="/z/d/graphic/96747.html" rel="external">
          figure 2
         </a>
         ). Capillary abnormalities can be detected by nailfold capillaroscopy. Gastrointestinal involvement is often asymptomatic. Thus, imaging such as esophageal technetium scintigraphy is necessary for diagnosis. The assessment of cardiac involvement is traditionally based on periodic monitoring with electrocardiography (ECG) and conventional echocardiography. The diagnosis of interstitial lung disease (ILD) in juvenile systemic sclerosis (JSSc) is based on pulmonary function tests (PFTs) and imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Treatment is divided into nonpharmacologic measures and pharmacologic therapy, which includes general immunomodulation and organ-targeted therapy. (See
         <a class="local">
          'Management overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – Nonpharmacologic measures include skin care, an exercise program, and the use of corrective splints. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunomodulation and organ-targeted therapy
         </strong>
         – The pharmacologic management of patients with JSSc is challenging because the etiology and pathogenesis are poorly understood and the disease is heterogenous with variable progression. The treatment of JSSc is mainly symptomatic and is tailored to the individual needs of the patient based upon their specific clinical manifestations of the disease and organ involvement. No drug has been shown to be of unequivocal benefit in either children or adults with SSc, and there are no randomized trials of these therapies in children with JSSc. (See
         <a class="local">
          'Immunomodulation'
         </a>
         above and
         <a class="local">
          'Organ-targeted therapy'
         </a>
         above and
         <a class="local">
          'Experimental therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Patients with JSSc have a significant risk of severe morbidity and can have a poor prognosis. JSSc is usually most active during the first three to five years following onset of disease. After the first five years of disease, constitutional symptoms often abate and skin abnormalities stabilize or occasionally improve, but visceral involvement may progress. The overall outcome in JSSc is better than in those with adult-onset SSc, with higher survival rates seen in children. The most common causes of death in children are related to the involvement of cardiac, kidney, and pulmonary systems. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Derrett-Smith EC. Juvenile-onset systemic sclerosis: children are not small adults. Rheumatology (Oxford) 2009; 48:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wozniak J, Dabrowski R, Luczak D, et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. J Rheumatol 2009; 36:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Civieri G, Castaldi B, Martini G, et al. Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography. Rheumatology (Oxford) 2021; 60:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi H, Yokoe I, Hirano M, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol 2009; 36:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Reyna TS, Morelos-Guzman M, Hernández-Reyes P, et al. Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. Rheumatology (Oxford) 2015; 54:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thuny F, Lovric D, Schnell F, et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. Radiology 2014; 271:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eid NS, Buchino JJ, Schikler KN. Pulmonary manifestations of rheumatic diseases. Pediatr Pulmonol Suppl 1999; 18:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foeldvari I, Klotsche J, Hinrichs B, et al. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. Arthritis Care Res (Hoboken) 2022; 74:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garty BZ, Athreya BH, Wilmott R, et al. Pulmonary functions in children with progressive systemic sclerosis. Pediatrics 1991; 88:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000; 55:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koker O, Adrovic A, Sahin S, et al. Evaluation of six-minute walk test in juvenile systemic sclerosis. Rheumatol Int 2019; 39:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000; 27:2692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford) 2006; 45:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melsens K, Cutolo M, Schonenberg-Meinema D, et al. Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study. Rheumatology (Oxford) 2023; 62:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004; 43:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini G, Cappella M, Culpo R, et al. Infrared thermography in children: a reliable tool for differential diagnosis of peripheral microvascular dysfunction and Raynaud's phenomenon? Pediatr Rheumatol Online J 2019; 17:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999; 42:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum 2012; 64:4143.
          </a>
         </li>
         <li class="breakAll">
          Zulian F. Systemic sclerodermas. In: Textbook of Pediatric Rheumatology, 7th ed, Perry RE, Laxer RM, Lindsley CB, Wedderburn LR (Eds), Saunders, Philadelphia 2015. p.384.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens AM, Torok KS, Li SC, et al. Immunopathogenesis of Juvenile Systemic Sclerosis. Front Immunol 2019; 10:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Tirelli F. Treatment in Juvenile Scleroderma. Curr Rheumatol Rep 2020; 22:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009; 48:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 2017; 76:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentini G, Paone C, La Montagna G, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulffraat NM, Vastert B, SHARE consortium. Time to share. Pediatr Rheumatol Online J 2013; 11:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foeldvari I, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford) 2021; 60:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013; 72:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008; 47:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini G, Vittadello F, Kasapçopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford) 2009; 48:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford) 2012; 51:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Namas R, Tashkin DP, Furst DE, et al. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken) 2018; 70:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panopoulos ST, Bournia VK, Trakada G, et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 2013; 191:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol 2014; 6:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinchcliff M, Toledo DM, Taroni JN, et al. Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. J Invest Dermatol 2018; 138:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambartsumyan L, Zheng HB, Iyer RS, et al. Relationship Between Esophageal Abnormalities on Fluoroscopic Esophagram and Pulmonary Function Testing in Juvenile Systemic Sclerosis. Arthritis Care Res (Hoboken) 2019; 71:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousa H, Hassan M. Gastroesophageal Reflux Disease. Pediatr Clin North Am 2017; 64:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy 2013; 33:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmanuel A. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol 2016; 13:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pittman N, Rawn SM, Wang M, et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology (Oxford) 2018; 57:1802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clin Exp Rheumatol 2011; 29:S22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron M, Bernier P, Côté LF, et al. Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol 2010; 28:S42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruni C, Praino E, Allanore Y, et al. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 2017; 13:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Balzarin M, Birolo C. Recent advances in the management of juvenile systemic sclerosis. Expert Rev Clin Immunol 2017; 13:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017; 46:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019; 78:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Dal Pozzolo R, Meneghel A, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford) 2020; 59:3793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380:2518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311:2490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 1999; 42:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 2006; 33:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 2000; 39:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 2006; 54:3971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002; 29:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Lanzoni G, Castaldi B, et al. Systemic sclerosis sine scleroderma in children. Rheumatology (Oxford) 2022; 61:2555.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 122988 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19028745" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Juvenile-onset systemic sclerosis: children are not small adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19040309" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32572491" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19040307" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239881" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24475856" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10093108" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pulmonary manifestations of rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33141441" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1956732" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pulmonary functions in children with progressive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10988042" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Computed tomography of diffuse interstitial lung disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30367202" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation of six-minute walk test in juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093455" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16174648" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36005889" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12923288" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31619252" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Infrared thermography in children: a reliable tool for differential diagnosis of peripheral microvascular dysfunction and Raynaud's phenomenon?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524696" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22886849" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A preliminary disease severity score for juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22886849" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A preliminary disease severity score for juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31293569" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Immunopathogenesis of Juvenile Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32591919" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Treatment in Juvenile Scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899504" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21378404" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846575" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188239" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27469583" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751093" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467039" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27941129" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Update of EULAR recommendations for the treatment of systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23414510" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Time to share.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33147624" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Consensus-based recommendations for the management of juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508437" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426043" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263597" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18854345" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Factors affecting survival in juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728264" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28544580" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23925736" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25276300" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cardiac manifestations in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8624641" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11407694" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22467932" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29391252" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30295423" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Relationship Between Esophageal Abnormalities on Fluoroscopic Esophagram and Pulmonary Function Testing in Juvenile Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28502434" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Gastroesophageal Reflux Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23712734" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27381075" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Current management of the gastrointestinal complications of systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29982822" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21586214" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20576213" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27899043" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of biologics and other novel therapies for the treatment of systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27690679" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Recent advances in the management of juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27839742" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30967395" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32442284" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Rituximab for rapidly progressive juvenile systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31112379" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058083" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29298160" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10211898" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16583463" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10852989" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133611" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12180742" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Severe cardiac involvement in children with systemic sclerosis and myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34605913" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Systemic sclerosis sine scleroderma in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
